Patrick Collison (Stripe) discusses why corporate bill payments remain reliant on manual PDF invoices and bank transfers with Eric Glyman (Ramp) and Alex Rampell (a16z).
“It seems like bill payment,
Has proven over the past 40 years uniquely resistant to automation and modernization.”
quote is from the automated transcript, cleaned for reading:
filler sounds and stutters are removed, nothing is rephrased. names can be misheard
(the analysis reads context, assessments check outside sources). how →
More from Patrick Collison
PredictionNot checkable as stated
Collison: Everything will pass through a transformer model before consumption
“Everything will pass through a transformer model before it's consumed.”
Patrick CollisonAug 27, 2025▶ 44:00A Cheeky Pint with Cognition CEO Scott Wu
Insight
Collison: B2B payments need a DNS-style central clearinghouse for bank accounts
“If you looked at the bill pay system from the outside, you would say, we should have DNS for companies.
So rather than a company
Like, sending you their bank account details.
You should, like, look them up in some central clearinghouse, and that way you confir…”
Patrick CollisonFeb 17, 2026▶ 13:42Ramp founder Eric Glyman on the many ways AI is changing corporate spending
Opinion
Collison: Big tech incumbents leave fewer AI opportunities on the table
“Clearly, all the large companies these days, they're very aware, they're very connected with the ecosystem. If you look at Asatia or Mark Zuckerberg, they are very aware of everything that's going on AI, and they're paying a lot of attention to it. And so, yea…”
Patrick CollisonAug 27, 2025▶ 7:51A Cheeky Pint with Cognition CEO Scott Wu
AssertionSupported
Collison: Median clinical trial enrollment costs $40,000 per patient
“The median clinical trial enrollee, it now costs 40,000 dollars.”
Patrick CollisonNov 11, 2025▶ 10:32Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
AssertionSupported
Collison: India's largest generic manufacturer paid a $500M fraud fine
“The largest generic manufacturer in India, I forget its name paid a half a billion dollar fine in 2013. Yeah, for rampant fraud and falsification and abuse of the biosimilarity analyses and so forth”
Patrick CollisonNov 11, 2025▶ 1:17:26Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Made with StarZero
Turn any episode into a week of clips.
This entire site, about 28 episodes transcribed, diarized, checked and made playable,
runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the
moments worth sharing, cuts them, captions them, and reframes them for every feed.
We use essential cookies to make the site work. With your permission we
also use analytics cookies (Google Analytics and Mixpanel) to understand
usage and improve StarZero. See our Cookie Policy.